Skip to main content
. 2014 Oct 31;19(12):1231–1240. doi: 10.1634/theoncologist.2014-0167

Figure 3.

Figure 3.

Abiraterone increases steroids with mineralocorticoid activity upstream of CYP17A1. Shown are median serum levels of corticosterone and deoxycorticosterone over time in patients with metastatic castration-resistant prostate cancer who received abiraterone acetate at doses of 250 to 2,000 mg daily. The right panel shows mean corticosterone levels at day 28 by abiraterone acetate dose [12].